Results 51 to 60 of about 64,353 (271)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma

Journal of Translational Medicine, 2023
Mesothelioma is a cancer typically caused by asbestos. Mechanistically, asbestos carcinogenesis has been linked to the asbestos-induced release of HMGB1 from the nucleus to the cytoplasm, where HMGB1 promotes autophagy and cell survival, and to the ...
Michele Carbone, Michael Minaai, Yasutaka Takinishi, Ian Pagano, Haining Yang   +4 more
doaj   +1 more source

Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model

Frontiers in Immunology, 2023
IntroductionMesothelioma is an aggressive tumor in the pleural cavity that is difficult to treat. Diagnosis is usually late with minimal treatment options available for the patients and with unfavorable outcomes. However, recent advances in immunotherapy
Ka Sin Lui, Zuodong Ye, Hoi Ching Chan, Yoshimasa Tanaka, Allen Ka Loon Cheung   +4 more
doaj   +1 more source

CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

Advanced Science, EarlyView.
Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen, Yinde Huang, Juntong Wu, Ziying Yi, Yao Li, Zeyu Yang, Fan Zhang, Chong Li   +7 more
wiley   +1 more source

Peritoneal mesothelioma [PDF]

Postgraduate Medical Journal, 1990
Summary We report two patients who presented with small bowel obstruction secondary to peritoneal mesothelioma. The difficulties in establishing this diagnosis at an early stage are illustrated. Recent advances in the management of peritoneal mesothelioma are reviewed.
J H, Anderson, C J, Stewart, D T, Hansell, J R, Anderson   +3 more
openaire   +2 more sources

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial

Nature Communications
Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive.
Dean A. Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y. Baitei, Joanna Dzialo, Nada Nusrat, Jan Rogel, Daniel Faulkner, Christian Ottensmeier, Raffaele Califano, Gerard G. Hanna, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Kim Mallard, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Liz Darlison, Peter Wells-Jordan, Cathy Richards, James Harber, Aleksandra Bzura, Jake Spicer, Catrin Pritchard, Tamihiro Kamata, Jens C. Hahne, Maymun Jama, Edward J. Hollox, Jason F. Lester, Jin-Li Luo, Zisen Zhou, Hongji Yang, Huiyu Zhou, Astero Klampatsa, Gareth O. Griffiths   +39 more
doaj   +1 more source

Twenty‐Year Longitudinal Cohort Study of Cancer Incidence and Mortality Among Workers in Two Primary Aluminum Prebake Smelters

American Journal of Industrial Medicine, EarlyView.
ABSTRACT Background Classified as carcinogenic to humans by the International Agency for Research on Cancer, aluminum production has been transitioning towards lower polycyclic aromatic hydrocarbon‐emitting prebake smelters. This study explored the risk of cancer and mortality over 20 years follow‐up among a cohort of aluminum prebake smelter workers ...
Natasha Kinsman, Christina Dimitriadis, Anthony Del Monaco, Geza Benke, Sophia Xie, Malcolm Sim, StellaMay Gwini, Karen Walker‐Bone   +7 more
wiley   +1 more source

Pleural mesothelioma [PDF]

Cancer, 1976
Seventy-six patients with pleural mesothelioma were seen at Memorial Hospital from 1939 to 1972. There were 10 with benign and 66 with malignant mesotheliomas. The latter were histologically divided into 39 epithelial and 27 fibrosarcomatous types. Main symptoms were chest pain, dyspnea, and cough.
H J, Wanebo, N, Martini, M R, Melamed, B, Hilaris, E J, Beattie   +4 more
openaire   +2 more sources

Circulating SMRP and CA‐125 before and after pleurectomy decortication for pleural mesothelioma

Thoracic Cancer
Background Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin‐related protein (SMRP) and cancer antigen 125 (CA‐125) are established blood‐based biomarkers for monitoring PM.
Juuso Paajanen, Ahmed Sadek, William G. Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R. Gill, Raphael Bueno   +8 more
doaj   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth

OncoImmunology, 2019
Versican promotes experimental tumor growth through cell- and non cell-autonomous mechanisms. Its role in mesothelioma progression has not been investigated so far.
Apostolos G. Pappas, Sophia Magkouta, Ioannis S. Pateras, Ioannis Skianis, Charalampos Moschos, Maria Eleni Vazakidou, Katherina Psarra, Vassilis G. Gorgoulis, Ioannis Kalomenidis   +8 more
doaj   +1 more source